Metropolis Healthcare Q1 profit rises 26% as TruHealth and Tier III markets outpace

Metropolis Healthcare reported Q1 FY27 revenue growth of 16.6% and a 210-basis-point EBITDA margin expansion. TruHealth revenue rose 22%, while Tier III markets grew about 25%, ahead of Tier I and II, as patient and test volumes increased without price hikes.

— Source publishedTue, 4 Aug, 2026, 20:21 IST·First seen Tue, 4 Aug, 2026, 20:24 IST·Source CNBC-TV18 · Companies

What happened

Metropolis Healthcare’s Q1 FY27 profit rose 26% as higher patient and test volumes lifted revenue and margins. TruHealth, specialty diagnostics and Tier III

Key facts

  • Consolidated net profit ₹57 crore, up 25.8% year-on-year from ₹45 crore
  • Revenue from operations ₹450 crore, up 16.6% from ₹386 crore
  • EBITDA ₹217 crore, up 22% year-on-year
  • EBITDA margin 48.3%, up from 46.1%
  • Patient volumes up 10%; test volumes up 11%
  • B2C revenue up 18%; B2B revenue up 15%
  • TruHealth revenue ₹81 crore, up 22%, representing about 18% of revenue
  • Specialty Diagnostics revenue ₹178 crore, up 17%, representing about 40% of revenue
  • Premium TruHealth packages grew over 50%; radiology-integrated wellness packages grew over 40%
  • Tier III revenue up about 25%, versus Tier I up 11% and Tier II up 14%
  • EBITDA margin expanded by 210 basis points

Why this matters

TruHealth’s 22% growth and roughly 25% Tier III-market growth identify high-priority expansion and partnership opportunities beyond mature Tier I and II markets.

What to watch

  • Whether patient and test-volume growth stays ahead of revenue growth, confirming demand is volume-led rather than price-led.
  • TruHealth growth rate, repeat usage, and its contribution to consolidated revenue and gross margin.
  • Tier III growth durability after new-center maturation, including same-center versus newly added network performance.
  • EBITDA-margin progression versus collection-center, logistics, and marketing investments.
  • Average revenue per patient and test mix, especially any dilution from preventive packages or competitive discounting.
  • Competitor pricing, diagnostic-chain expansion, and local referral-channel exclusivity in smaller cities.
  • Accelerate TruHealth cross-sell through preventive-health packages, chronic-disease monitoring, and employer or insurer partnerships.
  • Add collection centers, franchise or partner points, and sample-logistics capacity in high-growth Tier III clusters.
  • Prioritize test-menu expansion and digital repeat-booking tools to convert higher patient traffic into recurring revenue.
  • Use improving profitability to fund targeted geographic expansion while avoiding broad price discounting.
  • Increase local clinician, hospital, and pharmacy referral partnerships to defend customer acquisition economics.